Cisplatin
|
Catalog No.GC11908
One-Click Copy Product Info
|
Cisplatin, a platinum-containing anticancer drug, is one of the most commonly used cytotoxic agents for the treatment of a variety of solid malignant tumors.
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 15663-27-1
Sample solution is provided at 25 µL, 10mM.
- Commun Biol (2026).PMID:42393254
- Environ Toxicol (2024).PMID:38224486
- Int Immunopharmacol 147 (2025):114010.PMID:39765000
- Journal of Ethnopharmacology (2025):120368.PMID:40783104
- J Cell Commun Signal 19.1 (2025):e12058.PMID:39712859
- Med Oncol 43.5 (2026):181.PMID:42008005
- Biochem Biophys Rep 37 (2024):101655.PMID:38333051
- Displays (2025):103272.
- J Biophotonics (2025):e202500127.PMID:4039141
- Eur J Pharm Sci 152 (2020):105450.
- Pharmacol Res 179 (2022):106222.
- iScience (2023).PMID:37426352
- BioRxiv (2025):2025-06.
Cisplatin, a platinum-containing anticancer drug, is one of the most commonly used cytotoxic agents for the treatment of a variety of solid malignant tumors. Cisplatin generally binds with genomic DNA (gDNA) or mitochondrial DNA (mtDNA) to create DNA lesions, block the production of DNA, mRNA and proteins, arrest DNA replication, activate several transduction pathways which finally led to necrosis or apoptosis[1-2].
In vitro, Cisplatin (0-30μM; 12-24h) induced apoptosis in HeLa cells in a dose- and time-dependent manner[1]. Cisplatin (0-40μg/ml; 24h) inhibited melanoma cell growth in a dose-dependent manner, with IC50 at about 15μg/ml[3].
In vivo, Cisplatin (4mg/kg; i.p.; 3 times) inhibited tumor growth in a B16F0 melanoma-bearing mouse model[3]. Cisplatin (5mg/kg; i.p.; 2 weeks) can establish a mouse model of acute kidney injury, as evidenced by elevated levels of serum creatinine (SCr), blood urea nitrogen (BUN), neutrophil gelatinase-associated lipocalin (NGAL), and nitrotyrosine[4].
References:
[1] Wang X, Martindale JL, Holbrook NJ. Requirement for ERK activation in cisplatin-induced apoptosis. J Biol Chem. 2000;275(50):39435-39443.
[2] Stordal B, et al. Understanding cisplatin resistance using cellular models. IUBMB Life. 2007 Nov;59(11):696-9.
[3] Park HR, Ju EJ, Jo SK, Jung U, Kim SH, Yee ST. Enhanced antitumor efficacy of cisplatin in combination with HemoHIM in tumor-bearing mice. BMC Cancer. 2009;9:85. Published 2009 Mar 17.
[4] Noha Alassaf, et al. Autophagy and necroptosis in cisplatin-induced acute kidney injury: Recent advances regarding their role and therapeutic potential. Front Pharmacol. 2023 Jan 30:14:1103062.
| Cell experiment [1]: | |
|
Cell lines |
Melanoma cell |
|
Preparation Method |
The melanoma cells were seeded on to 96-well plates at a density of 7×103 cells per well in 100μl of media. After incubation for 24 hours, cells were treated with various concentration of Cisplatin for 24 hours. After incubation, a CCK-8 solution was added to each well. |
|
Reaction Conditions |
0-40μg/ml; 24h |
|
Applications |
Cisplatin inhibited melanoma cell growth in a dose-dependent manner, with IC50 at about 15μg/ml. |
| Animal experiment [1]: | |
|
Animal models |
B16F0 melanoma-bearing mouse model |
|
Preparation Method |
B16F0 melanoma (5×105 cells/mouse) was inoculated into subcutaneous femoral left region of mice at 3 days before an initial injection of Cisplatin. Cisplatin was injected intraperitoneally at 4mg/kg on day 0, 7 and 14 (total three injections). On day 17 after initial injection of Cisplatin, mice were experimented, respectively, to evaluate tumor weight or tumor size. |
|
Dosage form |
4mg/kg; i.p.; 3 times |
|
Applications |
In the Cisplatin-injected group, tumor weight (2.97g (±1.29)) and size (6.3mm3 (±2.32)) were reduced significantly in comparison to the control group. |
References: [1] Park HR, Ju EJ, Jo SK, Jung U, Kim SH, Yee ST. Enhanced antitumor efficacy of cisplatin in combination with HemoHIM in tumor-bearing mice. BMC Cancer. 2009;9:85. | |
| Cas No. | 15663-27-1 | SDF | |
| Synonyms | CDDP | ||
| Chemical Name | azane;dichloroplatinum(2+) | ||
| Canonical SMILES | N.N.Cl[Pt+2]Cl | ||
| Formula | Cl2H6N2Pt | M.Wt | 300.05 |
| Solubility | 5 mg/mL in DMF (16.66 mM; DMSO can inactivate Cisplatin's activity), 1 mg/mL in Water (3.33 mM; DMSO can inactivate Cisplatin's activity) | Storage | 4°C, protect from light |
| General tips | Please select the appropriate solvent to prepare the stock solution according to the
solubility of the product in different solvents; once the solution is prepared, please store it in
separate packages to avoid product failure caused by repeated freezing and thawing.Storage method
and period of the stock solution: When stored at -80°C, please use it within 6 months; when stored
at -20°C, please use it within 1 month. To increase solubility, heat the tube to 37°C and then oscillate in an ultrasonic bath for some time. |
||
| Shipping Condition | Evaluation sample solution: shipped with blue ice. All other sizes available: with RT, or with Blue Ice upon request. | ||
| Prepare stock solution | |||
|
1 mg | 5 mg | 10 mg |
| 1 mM | 3.3328 mL | 16.6639 mL | 33.3278 mL |
| 5 mM | 666.6 μL | 3.3328 mL | 6.6656 mL |
| 10 mM | 333.3 μL | 1.6664 mL | 3.3328 mL |
Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
g
μL
Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)
Calculation results:
Working concentration: mg/ml;
Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )
Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL saline, mix and clarify.
Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.
Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.
3. All of the above co-solvents are available for purchase on the GlpBio website.
Quality Control & SDS
- View current batch:
- Purity: >98.00% Appearance: A solid
- COA (Certificate of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
Average Rating: 5 (Based on Reviews and 32 reference(s) in Google Scholar.)